Magnetic resonance imaging in rheumatoid arthritis advances and research priorities

Mikkel Østergaard; FM McQueen; P Bird; B Ejbjerg; MN Lassere; CG Peterfy; PJ O'Connor; E Haavardsholm; R Shnier; HK Genant; P Emery; JP Edmonds; PG Conaghan

Magnetic resonance imaging in rheumatoid arthritis advances and research priorities

Mikkel Østergaard, FM McQueen, P Bird, B Ejbjerg, MN Lassere, CG Peterfy, PJ O'Connor, E Haavardsholm, R Shnier, HK Genant, P Emery, JP Edmonds, PG Conaghan

18 Citations (Scopus)

Abstract

Magnetic resonance imaging (MRI) has now been used extensively in cross-sectional and observational studies as well as in controlled clinical trials to assess disease activity and joint damage in rheumatoid arthritis (RA). MRI measurements or scores for erosions, bone edema, and synovitis have been developed and validated by several groups. The OMERACT criteria require that outcome measures demonstrate adequate validity, discriminative power, and feasibility if they are to be useful in clinical trials. Specific performance targets for these criteria depend on the scientific, regulatory, logistical, and financial context of the study in question. We review the extent to which MRI assessments of joint erosion, bone edema, and synovitis fulfil these criteria, particularly as they relate to proof-of-concept RA clinical trials.

Translated title of the contribution	Magnetic resonance imaging in rheumatoid arthritis advances and research priorities
Original language	English
Journal	Journal of Rheumatology
Volume	32
Issue number	12
Pages (from-to)	2462-4
ISSN	0315-162X
Publication status	Published - 2005

Access to Document

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16331788&query_hl=2&itool=pubmed_docsum

Cite this

Østergaard, M., McQueen, FM., Bird, P., Ejbjerg, B., Lassere, MN., Peterfy, CG., O'Connor, PJ., Haavardsholm, E., Shnier, R., Genant, HK., Emery, P., Edmonds, JP., & Conaghan, PG. (2005). Magnetic resonance imaging in rheumatoid arthritis advances and research priorities. Journal of Rheumatology, 32(12), 2462-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16331788&query_hl=2&itool=pubmed_docsum

Østergaard, M, McQueen, FM, Bird, P, Ejbjerg, B, Lassere, MN, Peterfy, CG, O'Connor, PJ, Haavardsholm, E, Shnier, R, Genant, HK, Emery, P, Edmonds, JP & Conaghan, PG 2005, 'Magnetic resonance imaging in rheumatoid arthritis advances and research priorities', Journal of Rheumatology, vol. 32, no. 12, pp. 2462-4. <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16331788&query_hl=2&itool=pubmed_docsum>

@article{5a466f54abd74c9589b2cf4cc5b9b744,

title = "Magnetic resonance imaging in rheumatoid arthritis advances and research priorities",

abstract = "Magnetic resonance imaging (MRI) has now been used extensively in cross-sectional and observational studies as well as in controlled clinical trials to assess disease activity and joint damage in rheumatoid arthritis (RA). MRI measurements or scores for erosions, bone edema, and synovitis have been developed and validated by several groups. The OMERACT criteria require that outcome measures demonstrate adequate validity, discriminative power, and feasibility if they are to be useful in clinical trials. Specific performance targets for these criteria depend on the scientific, regulatory, logistical, and financial context of the study in question. We review the extent to which MRI assessments of joint erosion, bone edema, and synovitis fulfil these criteria, particularly as they relate to proof-of-concept RA clinical trials.",

author = "Mikkel {\O}stergaard and FM McQueen and P Bird and B Ejbjerg and MN Lassere and CG Peterfy and PJ O'Connor and E Haavardsholm and R Shnier and HK Genant and P Emery and JP Edmonds and PG Conaghan",

year = "2005",

language = "English",

volume = "32",

pages = "2462--4",

journal = "Journal of Rheumatology",

issn = "0315-162X",

publisher = "Journal of Rheumatology Publishing Co. Ltd.",

number = "12",

}

TY - JOUR

T1 - Magnetic resonance imaging in rheumatoid arthritis advances and research priorities

AU - Østergaard, Mikkel

AU - McQueen, FM

AU - Bird, P

AU - Ejbjerg, B

AU - Lassere, MN

AU - Peterfy, CG

AU - O'Connor, PJ

AU - Haavardsholm, E

AU - Shnier, R

AU - Genant, HK

AU - Emery, P

AU - Edmonds, JP

AU - Conaghan, PG

PY - 2005

Y1 - 2005

N2 - Magnetic resonance imaging (MRI) has now been used extensively in cross-sectional and observational studies as well as in controlled clinical trials to assess disease activity and joint damage in rheumatoid arthritis (RA). MRI measurements or scores for erosions, bone edema, and synovitis have been developed and validated by several groups. The OMERACT criteria require that outcome measures demonstrate adequate validity, discriminative power, and feasibility if they are to be useful in clinical trials. Specific performance targets for these criteria depend on the scientific, regulatory, logistical, and financial context of the study in question. We review the extent to which MRI assessments of joint erosion, bone edema, and synovitis fulfil these criteria, particularly as they relate to proof-of-concept RA clinical trials.

AB - Magnetic resonance imaging (MRI) has now been used extensively in cross-sectional and observational studies as well as in controlled clinical trials to assess disease activity and joint damage in rheumatoid arthritis (RA). MRI measurements or scores for erosions, bone edema, and synovitis have been developed and validated by several groups. The OMERACT criteria require that outcome measures demonstrate adequate validity, discriminative power, and feasibility if they are to be useful in clinical trials. Specific performance targets for these criteria depend on the scientific, regulatory, logistical, and financial context of the study in question. We review the extent to which MRI assessments of joint erosion, bone edema, and synovitis fulfil these criteria, particularly as they relate to proof-of-concept RA clinical trials.

M3 - Journal article

SN - 0315-162X

VL - 32

SP - 2462

EP - 2464

JO - Journal of Rheumatology

JF - Journal of Rheumatology

IS - 12

ER -

Magnetic resonance imaging in rheumatoid arthritis advances and research priorities

Abstract

Access to Document

Fingerprint

Cite this